Internal Pipeline


Lantern Pharma collaborates with leading institutions, researchers and companies to develop and deliver cancer therapies.

Johns Hopkins

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

The collaboration will focus on advancing the targeted use of LP-184 in defined subtypes of GBM and clarifying the most promising clinical applications for the drug candidate. The goal of the collaboration is to utilize state of art laboratory and animal models of GBM as well as PDXs and neurospheres to precisely characterize the efficacy along with the CNS biovaiability and the PK/PD of the drug candidate. This will help streamline a clinically ready program with the most biologically relevant and robust genomic or biomarker signature and dosage and regimens for treatment of GBMs. By having a gene signature that can be used in identifying patients that have the potential for the highest response, Lantern can potentially accelerate future clinical trials and shorten the time to achieving patient benefit for GBM patients.

Fox Chase Cancer Center

Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer

The Fox Chase collaboration will focus on advancing the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer. The goal of the collaboration is to precisely identify the genomic and transcriptomic features of the most sensitive pancreatic cancers, understand the combinatorial synergies and define biologically relevant and robust gene signature that will be employed towards designing future clinical trials. Additional studies that will utilize unique gene dependencies of drug sensitivity to leverage multi modality treatments will help enable pancreatic cancer patients to potentially benefit from a more effective and personalized cancer therapy.

Georgetown University

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent

The first phase of the joint research activities with Georgetown, which began in the 4th quarter of 2019, generated strong evidence of the efficacy of LP-184 in prostate cancer and linked the anti-tumor activity to the presence of specific biomarkers. Phase one of the collaboration was a proof-of-concept study that demonstrated LP-184 had nanomolar potency across a wide variety of cell lines, as well as Prostate Cancer Organoids. In the next phase, gene centric studies have been conducted to precisely delineate the synthetic lethality of LP-184s efficacy in killing prostate cancer cells that have deficiency in Homologous recombination and Nucleotide Excision repair pathways. These studies strongly demonstrate that LP184 is an highly efficacious molecule for treatment of prostate cancers that overexpress PTGR1 and carry mutations in DNA damage repair genes including BRCA2, ERCC6 and others involved in homologous recombination and Nucleotide Excision repair.

National Cancer Institute

Lantern Pharma and National Cancer Institute Partner to Aid Precision Oncology Research and Treatments

Collaboration will leverage Lantern’s proprietary AI platform and NCI’s platform to guide pre-clinical studies and help unraveling the gene-drug dependency pathways to identify the most potent indications for drug development, provide a hypothesis generating platform to further feed wet lab collaborations with additional academic partners, understand the comparative features of LP184 with other standard of care and investigational drugs allowing to leverage the unique features of the drug and utilize the multiomics platforms to better predict patients’ tumor responses to specific drug classes and therapeutics

Danish Cancer Society Research Center (DCRC)

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center (DCRC) to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

The collaboration is expected to examine the most common solid tumors in order to determine the patient populations most likely to benefit from Lantern’s drug candidates LP-100 (irofulven) and LP-184. LP-100 and LP-184 have both shown to have a synthetically lethal impact in tumors that are lacking nucleotide excision repair (NER) capabilities. An additional aim of this collaboration will be to develop improved diagnostic tools to detect NER deficient patient profiles more accurately. Lantern expects the data, genomic signatures, and biological models generated from the collaboration to add millions of data points to RADR®. Dr. Zoltan Szallasi, M.D. will lead the collaboration for the DCRC.

UT Health San Antonio

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

The GCCRI research collaboration will focus on the effectiveness of Lantern's LP-184 and LP-284 in genomically-defined pediatric cancers, including several without any effective therapeutic approach. The collaboration will initially leverage GCCRI's pediatric tumor research models and knowledge base to advance Lantern's drug candidate, LP-184, for the treatment of rare pediatric cancers including rhabdomyosarcoma, Ewing sarcoma, MRT (malignant rhabdoid tumor), Wilms tumor, and ATRT (atypical teratoid rhabdoid tumor). Dr. Peter Houghton Ph.D. will lead the collaboration for the GCCRI and is widely regarded as leading expert on pediatric cancer research and in the development of novel approaches to treating childhood cancers.

InNovate with us

Partner with us

Learn more about partnering

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.